References

1.   1.      Gish RG, Lok AS, Chang TT, de Man RA, Gadano A, Sollano J, et al Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007 Nov;133(5):1437-44.

2.      Choudary A.Santra A Chakravorty A, Banarji A,Pal S, Dhali G K, et al Community-based epidemiology of hepatitis B virus infection in West Bengal, India: Prevalence of hepatitis B e antigen-negative infection and associated viral variants Journal of Gastroenterology and Hepatology November 2005.

3.      Lai CL, Yuen MF Chronic hepatitis B- New goals, new treatment. N Engl J Med. 2008 Dec 4;359(23):2488-91.

4.      Yang MF, Yuan HJ, Wong DK, Yuen JC, WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asian: therapeutic implications. Gut. 2005;54:1610-4.

5.      Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al Taiwan community –based cancer screening project group. Hepatitis B e antigen and the risk of hepatocellular carcinoma, N Engl J Ned. 200218;347(3):168-74.

6.      Perrillo RP, Marcellin P Effect of newer oral antiviral agents on future therapy of chronic hepatitis B, Antivir Ther. 2010;15(1):13-22.

7.      De Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, et al Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection Hepatology. 2001 Sep;34(3):578-82.

8.      Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, Dienstag JL, O’Brien C, Tamburro C, Jacobson IM, et al A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group N Engl J Med. 1990 Aug 2;323 (5): 295 -30

9.      Yao G, Chen C, Lu W, Ren H, Tan D, Wang Y, Xu D, Jiang Z, Liu J, Xu D, macdonald L; for the AI463023 Study Group Efficacy and safety of entecavir compared to lamivudine in nucleoside –naïve patients with chronic hepatitis B: a randomized double-blind trial in ChinaHepato Int. 2008Mar;2(1):136.

10.  Colonno RJ, Rose R Baldick CJ, Levine S, Pokornowski k, Yu CF, Walsh Entecavir resistance is rare in nucleoside naïve patients with hepatitis b Hepatology. 2006 Dec;44(6):1656-65.

11.  Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al Early Hepatitis B virus DNA Reduction in Hepatitis B e Antigen-positive Patients with Chronic Hepatitis B: A Randomized International Study of Entecavir Versus Adefovir Hepatology. 2009 Jan;49(1):72-9.

12.  Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC A comparison of entecavir and lamivudine for HBeAg-Positive chronic hepatitis B N Engl J Med. 2006 Mar 9;354(10):1001-10.

13.  Ren FY, Piao XX, A one-year trial of ETV in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007 : 13 (31): 4264-4267.

14.  Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J,et al Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009 May;49(5):1503-14.

15.  Lok AS, McMahon BJ; AASLD (American Association for the Study of Liver Disease). Chronic Hepatitis B: Update 2009 Hepatology 2009.

16.  Bihl F, Alaei M, Negro F. The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians. Swiss Wkly. 2010 Mar 20;140(11-12):154-9.

17.  Ren FY, Piao DM, Piao XX. A one-year trial of ETV in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007; 13(31):4264-4267.

18.  Sherman M. Yardaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R; AI463026 Benefits of Entecavir for Hepatitis b Liver Disease (BEHOLD) Study Group. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology. 2008 Jul;48(1):99-108.

19.  Yao GB, Ren H, Xu DZ, Zhou XQ, Jia JD, Wang YM, Chen CW. Results of 3 years of continuous entecavir treatment in nucleos(t)ide-naïve chronic hepatitis B patients Zhonghua Gan Zang Bing Za Zhi. 2009 Dec;17(12):881-6.

Corresponding Author

Jayanta Kumar Panda

Associate Professor, Dept. of Medicine, SCB Medical College, Cuttack

Email: This email address is being protected from spambots. You need JavaScript enabled to view it., Mob: 9437028282